Study of recombinant human interleukin-12 for treatment of complications after radiotherapy for tumor patients

Table 1 Results of whole blood test for the treatment group and the control group (mean ± SD, n = 10)

Group	Indicator	0 d	12 h	3 d	7 d	14 d	21 d	28 d
Control	WBC (× 109/L)	7.66 ± 0.82	5.5 ± 0.67	4.2 ± 0.39	4.3 ± 0.48	4.21 ± 0.62	4.69 ± 0.38	4.89 ± 0.63
	RBC (× 1012/L)	3.92 ± 0.31	4.26 ± 0.43	3.9 ± 0.41	3.93 ± 0.22	4.38 ± 0.36	3.86 ± 0.34	3.89 ± 0.28
	PLT (× 109/L)	358 ± 0.43	339 ± 31.45	232 ± 20.43	258 ± 19.2	275 ± 0.31	296 ± 0.29	321 ± 0.26
50 ng/kg	WBC (× 109/L)	6.31 ± 0.59	3.6 ± 0.35	4.27 ± 0.46	4.85 ± 0.35	4.52 ± 0.42	4.72 ± 0.39	5.18 ± 0.52
	RBC (× 1012/L)	5.43 ± 0.54	4.92 ± 0.53	4.16 ± 0.38	4.59 ± 0.82	4.73 ± 0.32	5.26 ± 0.37	5.63 ± 0.41
	PLT (× 109/L)	231 ± 20.81	185 ± 18.24	195 ± 18.97	205 ± 18	226 ± 18.2	246 ± 17.5	229 ± 19.4
100 ng/kg	WBC	8.4 ± 0.45	7.7 ± 7.89	5.3 ± 10.64	6.6 ± 0.98	6.1 ± 0.64	5.73 ± 0.47	5.9 ± 0.21
	RBC (× 1012/L)	6.3 ± 0.72	3.37 ± 0.43	3.2 ± 0.34	4.2 ± 0.37	4.78 ± 0.46	4.5 ± 0.42	4.6 ± 0.34
	PLT (× 109/L)	231 ± 27.2	185 ± 10.7	178 ± 12.6	195 ± 12.8	166 ± 10.9	182 ± 12.5	205 ± 15.3
150 ng/kg	WBC (× 109/L)	6.6 ± 0.73	5.4 ± 0.76	3.8 ± 0.35	5.2 ± 0.37	5.7 ± 0.42	6.2 ± 0.54	6.3 ± 0.54
	RBC (× 1012/L)	3.4 ± 0.36	3.5 ± 0.37	3.2 ± 0.29	3.3 ± 0.28	3.6 ± 0.24	3.6 ± 0.26	3.44 ± 0.21
	PLT (× 109/L)	367 ± 35.75	352 ± 32.45	306 ± 30.12	316 ± 16	357 ± 17	348 ± 26	317 ± 16
200 ng/kg	WBC (× 109/L)	5.3 ± 0.8	4.2 ± 0.3	3.2 ± 0.1	3.5 ± 0.32	3.6 ± 0.27	4.3 ± 0.31	5.4 ± 0.43
	RBC (× 1012/L)	4.6 ± 0.51	4.2 ± 0.41	4.1 ± 0.45	4.2 ± 0.3	4 ± 0.2	4.12 ± 0.34	4.5 ± 0.42
	PLT (× 109/L)	278 ± 36	183 ± 19	149 ± 14	208 ± 22	259 ± 24	267 ± 25	271 ± 21
250 ng/kg	WBC (× 109/L)	3.6 ±	3 ± 0.37	2.7 ± 0.24	3.4 ± 0.4	4.2 ± 0.3	4.5 ± 0.4	4.2 ± 0.4
	RBC (× 1012/L)	3.6 ± 0.3	3.3 ± 0.2	3.1 ± 0.2	3.2 ± 0.3	3.4 ± 0.3	3.7 ± 0.2	4.1 ± 0.3
	PLT (× 109/L)	364 ± 35	235 ± 21	240 ± 20	276 ± 22	314 ± 19	342 ± 21	312 ± 20

WBC: White blood cell; RBC: Red blood cell; PLT: Platelet.